HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G Could Be Last Suitor Standing For Pfizer's Consumer Health Business

This article was originally published in The Pink Sheet & The Rose Sheet

Executive Summary

A spin-off still is an option for Pfizer, as is continuing to operate the unit as it currently does. But P&G's apparent interest and dearth of other OTC business buyers changes the outlook for both companies.

You may also be interested in...



GSK And Reckitt Opting Out Of Pfizer's Consumer Business Sale Speaks Volumes

Reckitt and GSK withdraw from negotiating on potential deals for with Pfizer's consumer business, leaving slim chances Pfizer will receive an acceptable offer from other drug firms mentioned as potential suitors for the business, which it has valued at around $20bn. A spin-off could move to the fore.

P&G Extends Gum Repair Toothpaste Line As It Trims Production Footprint

P&G says harmful plaque bacteria below the gum line evades "even the most the diligent brushers." The firm plans in 2020 to move manufacturing of hair, oral and personal care products from Iowa to a facility in West Virginia.

P&G Goes Native In Acquisition That Aligns With Peltz' Recommendations

P&G purchase of Native deodorants likely is approved by activist investor and potential board member Nelson Peltz, who has pushed the firm to invest in small and local brands as well as natural products. It could be first in a series of tuck-in deals to help the firm compete with e-commerce start-ups.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel